LISDEXAMFETAMINE DIMESYLATE (lisdexamfetamine dimesylate) by PharmaIN is dextroamphetamine. Approved for ( ): attention deficit hyperactivity disorder (adhd) in adults, older moderate to severe binge eating disorder (bed) in adults limitations of use: pediatric patients with adhd younger than 6 years of age experienced more long-term weight loss than patients 6 years, older ( ) lisdexamfetamine dimesylate is not indicated for weight loss. First approved in 2023.
Drug data last refreshed 21h ago
dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.
Worked on LISDEXAMFETAMINE DIMESYLATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17